Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease

doi:10.3748/wjg.v25.i28.3664

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5491)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

474

HTML

3315

Figures (1-1)

180

Sum=3969

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

723

Download

799

Sum=1522

Jul 28, 2019 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jul 28, 2019; 25(28): 3664-3668
Published online Jul 28, 2019. doi: 10.3748/wjg.v25.i28.3664

Open in New Tab Full Size Figure Download Figure

Figure 1 Mechanisms implicated in the beneficial effects of sodium-glucose co-transporter-2 inhibitors on type 2 diabetes mellitus-associated nonalcoholic fatty liver disease.

Citation: Kontana A, Tziomalos K. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2019; 25(28): 3664-3668
URL: https://www.wjgnet.com/1007-9327/full/v25/i28/3664.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i28.3664